div class=trans-pagebuttonPage 1button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5page1jpg target=_blank amp-img class=trans-thumb alt=Page 1: Double-blind study of pardoprunox a new partial dopamine agonist in early Parkinson’s disease src=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 2button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5page2jpg target=_blank amp-img class=trans-thumb alt=Page 2: Double-blind study of pardoprunox a new partial dopamine agonist in early Parkinson’s disease src=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 3button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5page3jpg target=_blank amp-img class=trans-thumb alt=Page 3: Double-blind study of pardoprunox a new partial dopamine agonist in early Parkinson’s disease src=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 4button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5page4jpg target=_blank amp-img class=trans-thumb alt=Page 4: Double-blind study of pardoprunox a new partial dopamine agonist in early Parkinson’s disease src=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 5button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8deebfd68630a00b107html5page5jpg...